Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: A prospective study from China

Chinese Medical Journal

Volumn 124, Issue 20, 2011, Pages 3244-3248

  Song, Wei an ^a,b   Liu, Xi ^a   Tian, Xiao Dong ^a   Wang, Wei ^b   Liang, Chao Yang ^a   Zhang, Tao ^a   Guo, Jun Tang ^a   Peng, Yang Hong ^a   Zhou, Nai Kang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NAVY GENERAL HOSPITAL   (China)

Author keywords

Diagnosis; Lung neoplasm; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CHINA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HISTOLOGY; HUMAN; LUNG CANCER; LUNG NODULE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054850954     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.20.007     Document Type: Article

References (32)

1. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23: 143-152.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
4. Huang GJ, Mao YS, Zhang DC, Sun KL, He J, Cheng GY. Current status and future directions of surgery for lung cancer in China. Chin Med J 2007; 120: 619-621.
5. Henschke CI, Yankelevitz DF. CT screening for lung cancer: update 2007. Oncologist 2008; 13: 65-78.
6. Krotz D. Low-dose CT screening reduces lung cancer deaths. Diagn Imaging (San Franc) 2000; Suppl: 7-9.
7. Yankelevitz D. CT screening for lung cancer. AJR Am J Roentgenol 2003; 180: 1736-1737.
8. Finley RJ, Clifton J, Mayo J. Image-guided video-assisted thoracoscopic resection of small peripheral lung nodules. Adv Surg 2005; 39: 263-284.
9. Sortini D, Carcoforo P, Feo CV, Carrella G, Pozza E, Sortini A. Radiological examination for peripheral lung cancers and benign nodules less than 10 mm. Lung Cancer 2004; 45: 393-394.
10. Ma SH, Xu K, Huang T, Huang BJ, Zhu YS, Li J, et al. Relation of nm23 gene expression to CT sign and prognosis in peripheral nonsmall cell lung cancer. Chin Med J 2005; 118: 497-501.
11. Kumarasinghe P, Jayasundera CI. Cytological diagnosis of bronchial malignancies using the fibreoptic bronchoscope. Ceylon Med J 1992; 37: 41-43.
12. Yang YJ, Cheng DY, Fang X, Li XX. The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer. J Sichuan Univ (Med Ed) 2007; 38: 312-315.
13. Podbielski FJ, Rodriguez HE, Brown AM, Blecha MJ, Salazar MR, Connolly MM. Percutaneous biopsy in evaluation of lung nodules. JSLS 2004; 8: 213-216.
14. Raj Behl P, Hilton CJ, Holden MP. Mediastinoscope: another use. J Cardiovasc Surg (Torino) 1986; 27: 236-237.
15. Veronesi G, Bellomi M, Veronesi U, Paganelli G, Maisonneuve P, Scanagatta P, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 2007; 84: 959-965.
16. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006; 42: 1-41.
17. Sanchez de Cos Escuin J, Hernandez Hernandez J. Tumor markers and lung cancer. What's new? Arch Bronconeumol 2004; 40 Suppl 6: 35-40.
18. Niewoehner DE, Rubins JB. Clinical utility of tumor markers in the management of non-small cell lung cancer. Methods Mol Med 2003; 75: 135-141.
19. Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003; 23: 4277-4281.
20. Vinolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, et al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res 1998; 18: 631-634.
21. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005; 40: 90-97.
22. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260-271.
23. Vassilakopoulos T, Troupis T, Sotiropoulou C, Zacharatos P, Katsaounou P, Parthenis D, et al. Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer 2001; 32: 137-144.
24. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48: 1931-1937.
25. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: 1488-1495.
26. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995; 108: 163-169.
27. Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 1996; 77: 1274-1277.
28. Sanchez De Cos J, Masa F, de la Cruz JL, Disdier C, Vergara C. Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest 1994; 105: 773-776.
29. Bates J, Rutherford R, Divilly M, Finn J, Grimes H, O'Muircheartaigh I, et al. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J 1997; 10: 2535-2538.
30. Lagarde A, Forgach T, Nagy D, Nagy K, Vasas S, Janoki GA. Diagnostic sensitivity of three tumour markers in non-small cell lung cancer: a pilot study. Nucl Med Rev Cent East Eur 2000; 3: 139-142.
31. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008; 29: 371-380.
32. Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 2001; 21: 3085-3092.